These results further validate the selectivity of TES-1025 for the enzyme and consolidate the knowledge about ACMSD as a promising therapeutic target (Katsyuba et al., 2018; Kellum and Prowle, 2018; Kellum et al., 2020; Manrique-Caballero et al., 2021) for the recovery of the de novo NAD+ biosynthesis pathway and the maintaining of NAD+ homeostasis impaired in hepatic (Zhou et al., 2016) and renal diseases (Poyan Mehr et al., 2018). This evidence concerns the gene ACMSD and kidney disorder.